Patents by Inventor Laura Price

Laura Price has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230225595
    Abstract: A system comprising an adjustable mount arm, a bronchoscope coupled to the adjustable mount arm, an attachment coupled to the bronchoscope, and a steerable sheath coupled to the attachment and configured to be inserted through the bronchoscope. The system further includes a flexible probe configured to be inserted through the steerable sheath and the bronchoscope.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 20, 2023
    Inventors: Louis Mingione, Daniel Price, Kevin Royalty, Jeffrey Bissing, Samantha Weber, Nathan Clemans, Laura Wiley, Nathan Wallace, Eric Bielefeld
  • Publication number: 20220073636
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 10, 2022
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Patent number: 11180567
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 23, 2021
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Publication number: 20190100595
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 4, 2019
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Patent number: 10196451
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 5, 2019
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Publication number: 20180200152
    Abstract: Adult necklace and infant teething devices are disclosed that among other things have the appearance of small pieces that if they were as appeared might pose a choking hazard if disassembled but are actually made of larger pieces—modular units—that do not pose a choking hazard if separated from the necklace. In this way, the wearer may look fashionable but also have a safe teething device ready for an infant to use while being held by the wearer. Other aspects are disclosed.
    Type: Application
    Filed: January 17, 2017
    Publication date: July 19, 2018
    Inventor: Laura Price
  • Publication number: 20180051091
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: August 3, 2017
    Publication date: February 22, 2018
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Patent number: 9765150
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 19, 2017
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Publication number: 20160075790
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: November 24, 2015
    Publication date: March 17, 2016
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Patent number: 9228018
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: January 5, 2016
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITED
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 8981072
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 17, 2015
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Publication number: 20150023976
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Patent number: 8895010
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: November 25, 2014
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Publication number: 20140099707
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicants: DOMANTIS LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Steven G. NADLER, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 8473355
    Abstract: A system and method for electronic wallet conversion allows conversion of a basic electronic wallet to a more flexible wallet account, providing additional services and requiring additional authentication. The basic accountholder eventually requires the additional services provided by the more flexible wallet, typically editing rights and making purchases at sites requiring authentication beyond the basic level. To convert the account, the account holder is presented with a one-time challenge and response mechanism that requires the accountholder to summon information that only the account holder would know. If a successful match is made, the account is converted to the more flexible account for all time. The accountholder replaces the one-time challenge and response with a second-level password that grants the accountholder ongoing access to more sensitive wallet features, such as the ability to purchase at sites requiring a second-level password, and editing rights to the information stored in the wallet.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: June 25, 2013
    Assignee: Facebook, Inc.
    Inventors: Benjamin Quigley, Robert Sandler, Fletcher Jones, Rajesh Mahajan, Prakash Muppirala, David Lowe, Laura Price, Seth Goldstein, Venkatesh Subramanya, Jai Rawat
  • Publication number: 20130124407
    Abstract: A system and method for electronic wallet conversion allows conversion of a basic electronic wallet to a more flexible wallet account, providing additional services and requiring additional authentication. The basic accountholder eventually requires the additional services provided by the more flexible wallet, typically editing rights and making purchases at sites requiring authentication beyond the basic level. To convert the account, the account holder is presented with a one-time challenge and response mechanism that requires the accountholder to summon information that only the account holder would know. If a successful match is made, the account is converted to the more flexible account for all time. The accountholder replaces the one-time challenge and response with a second-level password that grants the accountholder ongoing access to more sensitive wallet features, such as the ability to purchase at sites requiring a second-level password, and editing rights to the information stored in the wallet.
    Type: Application
    Filed: September 15, 2012
    Publication date: May 16, 2013
    Applicant: FACEBOOK, INC.
    Inventors: Benjamin Quigley, Robert Sandler, Fletcher Jones, Rajesh Mahajan, Prakash Muppirala, David Lowe, Laura Price, Seth Goldstein, Venkatesh Subramanya, Jai Rawat
  • Publication number: 20130124408
    Abstract: A system and method for electronic wallet conversion allows conversion of a basic electronic wallet to a more flexible wallet account, providing additional services and requiring additional authentication. The basic accountholder eventually requires the additional services provided by the more flexible wallet, typically editing rights and making purchases at sites requiring authentication beyond the basic level. To convert the account, the account holder is presented with a one-time challenge and response mechanism that requires the accountholder to summon information that only the account holder would know. If a successful match is made, the account is converted to the more flexible account for all time. The accountholder replaces the one-time challenge and response with a second-level password that grants the accountholder ongoing access to more sensitive wallet features, such as the ability to purchase at sites requiring a second-level password, and editing rights to the information stored in the wallet.
    Type: Application
    Filed: September 15, 2012
    Publication date: May 16, 2013
    Applicant: FACEBOOK, INC.
    Inventors: Benjamin Quigley, Robert Sandler, Fletcher Jones, Rajesh Mahajan, Prakash Muppirala, David Lowe, Laura Price, Seth Goldstein, Venkatesh Subramanya, Jai Rawat
  • Publication number: 20100332336
    Abstract: A system and method for electronic wallet conversion allows conversion of a basic electronic wallet to a more flexible wallet account, providing additional services and requiring additional authentication. The basic accountholder eventually requires the additional services provided by the more flexible wallet, typically editing rights and making purchases at sites requiring authentication beyond the basic level. To convert the account, the account holder is presented with a one-time challenge and response mechanism that requires the accountholder to summon information that only the account holder would know. If a successful match is made, the account is converted to the more flexible account for all time. The accountholder replaces the one-time challenge and response with a second-level password that grants the accountholder ongoing access to more sensitive wallet features, such as the ability to purchase at sites requiring a second-level password, and editing rights to the information stored in the wallet.
    Type: Application
    Filed: October 20, 2003
    Publication date: December 30, 2010
    Inventors: Benjamin Quigley, Robert Sandler, Fletcher Jones, Rajesh Mahajan, Prakash Muppirala, David Lowe, Laura Price, Seth Goldstein, Venkatesh Subramanya, Jai Rawat
  • Publication number: 20060110792
    Abstract: This invention relates generally to a new family of potassium channels. More particularly, the present invention relates to the cloning and characterization of a family of distinct trans-membrane potassium ion channels, characterization of such channels, newly identified polynucleotide sequences, polypeptides encoded by such sequences, expression vectors capable of heterologous expression of such polynucleotide sequences, transformed host cells containing the expression vectors, and assay methods and kits therefor for determining the expression of heterologous nucleotide sequences encoding all or a portion of said potassium channels in host cells, chromosome mapping, diagnostic methodologies and kits therefore. Genes encoding potassium channels representative of this family were cloned from Drosophila melanogaster, Caenorhabditis elegans, human and mouse ESTs, and human brain, heart and kidney cDNA libraries.
    Type: Application
    Filed: July 12, 2005
    Publication date: May 25, 2006
    Inventors: Mark Pausch, Laura Price
  • Publication number: 20050086068
    Abstract: A system and method for electronic wallet conversion allows conversion of a basic electronic wallet to a more flexible wallet account, providing additional services and requiring additional authentication. The basic accountholder eventually requires the additional services provided by the more flexible wallet, typically editing rights and making purchases at sites requiring authentication beyond the basic level. To convert the account, the account holder is presented with a one-time challenge and response mechanism that requires the accountholder to summon information that only the account holder would know. If a successful match is made, the account is converted to the more flexible account for all time. The accountholder replaces the one-time challenge and response with a second-level password that grants the accountholder ongoing access to more sensitive wallet features, such as the ability to purchase at sites requiring a second-level password, and editing rights to the information stored in the wallet.
    Type: Application
    Filed: October 20, 2003
    Publication date: April 21, 2005
    Inventors: Benjamin Quigley, Robert Sandler, Fletcher Jones, Rajesh Mahajan, Prakash Muppirala, David Lowe, Laura Price, Seth Goldstein, Venkatesh Subramanya, Jai Rawat